Quantcast

NWC Physicians Respond to Recent Article; Shocking Statistics About Alzheimer’s Disease*

July 31, 2013

Alzheimer's is by far the most expensive disease in America yet the National Institutes of Health (NIH) research budget for Alzheimer's is $484 million; in contrast, the cancer research budget is $5.6 billion.

(PRWEB) July 31, 2013

In his State of the Union address President Obama called on congress to provide funding to "unlock the answers to Alzheimer's." The cost trajectory for this disease is staggering. "Nationwide, the total cost of caring for those with Alzheimer’s and other forms of dementia is estimated to be $203 billion in 2013, increasing to $1.2 trillion annually (in today’s dollars) by mid-century," according to the July 2013 article published in The Prime. Presently there are five FDA approved drugs for the treatment of Alzheimer's disease. The vast majority of the enormous expense of Alzheimer's is not the cost of the drugs but the cost of care due to the fact that the drugs fail to work at all or provide only a modest slowing of the disease progression. In 2006 the Journal Medscape published the results of a pilot study reporting a substantial recovery of memory and cognitive function among a group of fifteen people with moderate to severe Alzheimer's disease utilizing the anti-inflammatory biologic drug etanercept (Enbrel).** This study's lead author Edward Tobinick reported that all fifteen individuals improved significantly as determined by standardized testing. He sites a case of an "82-year-old, right-handed man who presented with effort of speech, word-finding impairment, and difficulty remembering names of people and places approximately 10 years ago. Antidepressant medication was prescribed. An examination in 1997 revealed numerous deficits involving naming, attention, memory, verbal comprehension, and visuospatial skills. His speech, according to his wife, included paraphasic errors and incorrect word sequencing. His MMSE score in 1997 was 19. Results of MRI of the brain performed in 1996 and 1997 were normal except for mild, diffuse atrophy. Single-photon emission computed tomography (SPECT) of the brain in 1996 showed hypoperfusion in the right parietal region. SPECT of the brain in 1998 and 2001 demonstrated severe hypoperfusion in the posterior parietal cortex bilaterally, thought most likely to represent advanced AD. History includes pacemaker placement and hypercholesterolemia. Thyroid-stimulating hormone and vitamin B12 level were within normal limits."

"Despite treatment with donepezil 10 mg/day, begun in 1998, the patient's cognitive status continued to decline. Repeat cognitive testing in 2001 included an MMSE score of 11, with evidence of apraxia as well as progressive impairments of gross cognitive functioning, attention, concentration, language skills, visuospatial abilities, verbal memory, and executive functioning. Because of cognitive worsening, donepezil was replaced with galantamine in 2001. By early 2003, the MMSE score declined to 7, and memantine was added. Despite combination therapy with galantamine 24 mg/day and memantine 10 mg orally twice daily, cognitive function deteriorated relentlessly, with MMSE scores falling to 4 and 0 by September 2004 and January 2005, respectively."

"In March 2005, after informed consent, he was begun on weekly doses of etanercept 25 mg given by perispinal administration. After 1 month, his speech was more fluent and daily activities, such as removing his jacket and shoes, were improved. After 5 months, he was more aware of his surroundings, more interactive with others, and better able to speak. His functional ability to perform daily activities, as measured by the use of the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev),[40] a standardized and validated structured questionnaire, was 20 at baseline, improved to 23 at 3 months, 26 at 4 months, 27 at 5 months, and 27 at 6 months. The patient's SIB and MMSE scores markedly improved with treatment, with MMSE improving from 0 to 4, and SIB improving 35 points."

Currently privately funded clinical trials evaluating the efficacy of perispinally administered etanercept (PSE) are underway in the U.S., UK, Australia and Nicaragua. Reports from physicians treating Alzheimer's with PSE generally confirm the findings Dr. Tobinick reported in his pilot study. A Google search of news reports, videos and blogs finds a number of instances where loved ones, caregivers and the Alzheimer's patients themselves report improvements in memory, mood and cognitive function with this treatment according to Rolando Hernandez, neurosurgeon for Neurological Wellness Center. "PSE is the only known treatment shown to reverse Alzheimer's disease and yet not one dollar of NIH funds have been devoted to this. The history of medicine is replete with examples where effective treatments languish for decades before they enter into widespread use. Consider local anesthesia. The first injection of local anesthetic for pain relief took place in 1884, yet the procedure did not come into widespread use in dentistry until the mid 1940s. Dentists were still extracting teeth without anesthesia decades after the invention of procaine (which is still in use today) in 1904. The fiscal implications alone for failing to bring effective Alzheimer's treatment into widespread use are catastrophic for individuals, families and even the entire Medicare system," stated Dr. Hernandez.

Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from Alzheimer's disease utilizing perispinal injections of etanercept since 2010. Although the precise causes of Alzheimer's disease are still unknown, there is a growing body of evidence linking chronic inflammatory events in the brain with the onset and progression of AD. Etanercept (Enbrel) is a drug approved to treat the acute inflammatory processes involved in certain forms of arthritis and psoriasis.

Perispinal injections are simple subcutaneous injections, performed with a fine gauge ½ inch needle, administered to the soft fatty tissue in the back of the neck. Neurological Wellness Center offers a complete two-hour course on Alzheimer's treatment, stroke treatment and traumatic brain injury treatment covering all aspects of perispinal injection technique at their center in Managua Nicaragua.

For many, flying to Neurological Wellness Center in Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 37-page e-book are now available online at http://www.neurological-recovery-guide.com.

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.

The drug Enbrel is available now. Enbrel received FDA approval in 1998. Its safety profile is well understood. For Enbrel to effectively treat Alzheimer’s, stroke and TBI, it must be administered to the back of the neck precisely between the cervical vertebrae C-5 and C-6. This perispinal injection allows Enbrel to enter the brain by lymph drainage assisted by gravity. Fortunately for the millions of people now afflicted with Alzheimer’s, stroke and TBI, a video is now available online detailing in step-by-step fashion how to administer a perispinal injection of Enbrel,” said Dr. Rolando Hernandez.

To enroll in a hands-on instructional course on perispinal injections, visit http://reversealzheimersnow.com/.

To purchase an instructional video and e-book on administering perispinal injections, visit http://www.neurological-recovery-guide.com/.

*http://blogs.courier-journal.com/prime/bhackbarth/2013/07/05/shocking-statistics-about-alzheimers-disease/

**http://www.ncbi.nlm.nih.gov/pubmed/16926764

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10904569.htm


Source: prweb



comments powered by Disqus